Diamyd Medical AB Stock price

Equities

DMYD B

SE0005162880

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:59:57 2024-03-28 am EDT 5-day change 1st Jan Change
10.48 SEK -2.42% Intraday chart for Diamyd Medical AB -4.03% +59.51%
Sales 2024 * 3M 280K Sales 2025 * 3M 280K Capitalization 1.02B 95.19M
Net income 2024 * -152M -14.19M Net income 2025 * -202M -18.86M EV / Sales 2024 * 324 x
Net cash position 2024 * 49M 4.57M Net cash position 2025 * 49M 4.57M EV / Sales 2025 * 324 x
P/E ratio 2024 *
-6.71 x
P/E ratio 2025 *
-5.04 x
Employees 25
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.58%
More Fundamentals * Assessed data
Dynamic Chart
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Diamyd Medical to Raise SEK114 Million Via Share Offering MT
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA CI
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment MT
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production CI
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine Phase 3 Trial, DIAGNODE-3, for Type 1 Diabetes Is Planned for July 2024 CI
Certain B Shares of Diamyd Medical AB are subject to a Lock-Up Agreement Ending on 27-DEC-2023. CI
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea CI
Diamyd Medical AB Elects Karin Rosén as A New Member of the Board CI
Diamyd Medical Partners With DiaUnion for Diabetes Drug Trial MT
Diamyd Medical Partners with Diamyd Medical to Recruit Participants for Type 1 Diabetes Prevention Trial CI
Diamyd Medical Raises SEK78 Million from Partially Subscribed Rights Issue MT
Diamyd Medical to Raise SEK78 Million from Partially Subscribed Rights Issue; Stock Jumps MT
Diamyd Medical Reports Updated Data on Subcutaneous Treatment to Delay Type 1 Diabetes Onset in Kids MT
More news

Latest transcript on Diamyd Medical AB

1 day-2.42%
1 week-5.07%
Current month-28.90%
1 month-27.82%
3 months+57.59%
6 months+30.67%
Current year+59.51%
More quotes
1 week
10.16
Extreme 10.16
11.06
1 month
10.16
Extreme 10.16
15.34
Current year
6.47
Extreme 6.47
20.00
1 year
6.41
Extreme 6.41
21.50
3 years
6.41
Extreme 6.41
39.84
5 years
6.29
Extreme 6.29
74.70
10 years
2.85
Extreme 2.85
74.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 16-04-09
Founder 83 95-12-31
Director of Finance/CFO 63 09-12-31
Members of the board TitleAgeSince
Founder 83 95-12-31
Director/Board Member 63 11-12-31
Director/Board Member 52 21-04-27
More insiders
Date Price Change Volume
24-03-28 10.48 -2.42% 69 583
24-03-27 10.74 +1.13% 209,089
24-03-26 10.62 -1.67% 132,329
24-03-25 10.8 -1.46% 254,359
24-03-22 10.96 -0.72% 88,462

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 06:02 am EDT

More quotes
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Diamyd Medical AB - Nasdaq Stockholm